Ignite Creation Date:
2025-12-25 @ 3:23 AM
Ignite Modification Date:
2026-03-11 @ 11:24 PM
Study NCT ID:
NCT03994705
Status:
TERMINATED
Last Update Posted:
2025-05-15
First Post:
2019-06-19
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor:
Cartesian Therapeutics
Organization:
Study Overview
Official Title:
Phase I Safety Study of Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Status:
TERMINATED
Status Verified Date:
2025-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Phase 1 enrollment completed. Further clinical development terminated.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 5R44CA221432-03 | NIH | None | https://reporter.nih.gov/quic… | View |